Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

07 juil. 2026 08h00 HE | Source: Arnatar Therapeutics, Inc.

Arnatar Therapeutics Receives China NMPA Clearance to Initiate First-in-Human Study of ART5, a First-in-Class Up-Regulating ASO Designed to Restore Polycystin-1 for the Treatment of ADPKD

ART5 is designed to address the most common root cause of ADPKD by targeting PKD1, potentially restoring PC1 production in approximately 85% of patientsFirst-in-human SAD study in healthy volunteers...
20 oct. 2025 08h00 HE | Source: Arnatar Therapeutics, Inc.

Arnatar Therapeutics Announces Upcoming Presentations at AASLD The Liver Meeting® 2025 and ASN Kidney Week 2025

SAN DIEGO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Arnatar Therapeutics, a biotechnology company pioneering RNA-based therapies for severe and underserved diseases, today announced that new preclinical...
25 août 2025 08h00 HE | Source: Arnatar Therapeutics, Inc.

Arnatar Therapeutics Emerges from Stealth and Announces Receipt of FDA Orphan Drug and Rare Pediatric Disease Designations for ART4

SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Arnatar Therapeutics, a biotechnology company pioneering RNA-based therapies for severe and underserved diseases, emerges from stealth today and...